Breast Cancer Clinical Trial
Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain
Summary
The study utilizes a 3-arm placebo-controlled RCT to study the effectiveness of ketamine in reducing chronic post-mastectomy pain. Participants randomized to the first arm will receive a 0.35 mg/kg dose after induction, followed by a 0.25 mg/kg/hr infusion during surgery (up to a maximum of 6 hours) and continued for 2 hours postoperatively. Participants in the second arm will receive a single dose of 0.6 mg/kg of ketamine in the post-anesthesia care unit, and the final group will serve as the control group and receive saline (no ketamine).
Eligibility Criteria
Inclusion Criteria:
Woman 18 years of age or older
Undergoing elective breast surgery for oncologic indication as follows: unilateral or bilateral mastectomy, prophylacticmastectomy, +/- lymph node dissection, +/- immediate or delayed reconstruction.
No distant metastases
Exclusion Criteria:
History of cognitive impairment or clinical signs of altered mental status (AMS) that may interfere with adherence to study procedures and/or participant safety. Clinical signs of AMS may include but are not limited to: confusion, amnesia, disorientation, fluctuating levels of alertness, etc.
Past ketamine or phencyclidine misuse or abuse
Schizophrenia or history of psychosis
History of post-traumatic stress disorder
Known sensitivity or allergy to ketamine
Liver or renal insufficiency
History of uncontrolled hypertension, chest pain, cardiac arrhythmia, stroke, head trauma, intracranial mass or hemorrhage, glaucoma, porphyria, uncontrolled thyroid disease, or other contraindication to ketamine
Lamotrigine, alfentanil, physostigmine, or 4-aminopyridine use
Currently Pregnant
Body mass index (BMI) greater than 35
Non-English or non-Spanish speaker
Currently participating in another pain interventional trial
Unwilling to comply with all study procedures and be available for the duration of the study
Patient is American Society of Anesthesiologists (ASA) physical status 4, 5, or 6
Patient has started or undergone hormone therapy for gender transition into male.
Patient scheduled for any bilateral (or greater) flap reconstruction
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 12 Locations for this study
Chicago Illinois, 60612, United States More Info
Principal Investigator
Chestnut Hill Massachusetts, 02467, United States More Info
Principal Investigator
Rochester Minnesota, 55905, United States More Info
Principal Investigator
Saint Louis Missouri, 63110, United States More Info
Principal Investigator
Bronx New York, 10467, United States More Info
Principal Investigator
New York New York, 10016, United States More Info
Principal Investigator
New York New York, 10016, United States More Info
Principal Investigator
New York New York, 10032, United States More Info
Principal Investigator
New York New York, 10065, United States More Info
Principal Investigator
Pittsburgh Pennsylvania, 15213, United States More Info
Principal Investigator
Dallas Texas, 75390, United States More Info
Principal Investigator
Houston Texas, 77030, United States More Info
Principal Investigator
Seattle Washington, 98195, United States More Info
Principal Investigator
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.